APRE
Aprea Therapeutics, Inc.
There isn't enough reported data to score APRE yet.
APRE Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
APRE's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
APRE PE Valuation
APRE has no meaningful PE right now: it lost money over the past year.
APRE Forward outlook
There aren't enough analyst estimates for APRE to show an outlook.
APRE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.65 | +$1.57 |
| Q2 2026 | -$1.03 | +$1.36 |
| Q1 2026 | -$1.49 | +$0.95 |
| Q4 2025 | -$1.93 | +$0.52 |
| Q3 2025 | -$2.22 | +$0.56 |
| Q2 2025 | -$2.39 | +$0.60 |
| Q1 2025 | -$2.44 | +$0.84 |
| Q4 2024 | -$2.45 | +$1.50 |
APRE is still losing money, but far less than before: $0.65 per share over the past year, against $110.00 at its worst in mid-2022.
APRE Quarterly Revenue
APRE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | -$3.5M | +$235.9K |
| Q2 2024 | -$3.6M | -$432.2K |
| Q1 2024 | -$3.9M | -$964.8K |
| Q4 2023 | -$3.7M | +$273.7K |
| Q2 2023 | -$3.2M | +$5.7M |
| Q1 2023 | -$3M | +$2.5M |
| Q4 2022 | -$4M | +$6.2M |
| Q4 2021 | -$10.2M | +$3M |
APRE has burned cash in almost every quarter: −$12M over the past year, against −$15M the year before.
APRE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +197K shares |
| 1 year | +782% | +47.6M shares |
| 3 years | +1546% | +50.4M shares |
| 5 years | +4980% | +52.6M shares |
APRE has 54M diluted shares, up 782% from a year ago.
APRE Net Leverage
APRE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
APRE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 9.4 | Oversold |
APRE's weekly RSI is 33 (neutral) and its Stochastic is 9 (oversold).
APRE PE vs Healthcare Sector
APRE has no meaningful PE right now: it lost money over the past year.
APRE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.58 | 24% below |
| 20 week MA | $0.66 | 33% below |
| 50 week MA | $0.77 | 43% below |
| 100 week MA | $1.42 | 69% below |
| 200 week MA | $2.98 | 85% below |
APRE is in a downtrend: it's below all five of its weekly moving averages, and 85% below its 200-week average.
APRE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $990.6 | $501.8 | -49% |
| 2021 | $501.8 | $67.4 | -87% |
| 2022 | $67.4 | $7.42 | -89% |
| 2023 | $7.42 | $4.70 | -37% |
| 2024 | $4.70 | $3.37 | -28% |
| 2025 | $3.37 | $0.98 | -71% |
| 2026 YTD | $0.98 | $0.44 | -55% |
APRE has finished every year since 2020 lower, and it's down 55% so far in 2026.